# Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)

> **NCT07489911** · — · RECRUITING · sponsor: **Chiesi Slovenija, d.o.o.** · enrollment: 200 (estimated)

## Conditions studied

- Asthma
- Asthma Patients
- Asthma Bronchiale

## Interventions

- **DRUG:** BDP/FF/G (beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium) 172/5/9 μg

## Key facts

- **NCT ID:** NCT07489911
- **Lead sponsor:** Chiesi Slovenija, d.o.o.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-04
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07489911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07489911, "Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT07489911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*